FLGT

Fulgent Genetics, Inc.

Nasdaq· Services-Medical Laboratories· Inc. DE· CIK 0001674930 Healthcare & Medical Devices

$20.42 +0.20 (+0.99%)

Oct 27 4:00 PM ET · prev $20.22

Market cap

$553.1M

Small cap

Consensus

Sell

0% Buy or better · 6 analysts

Median target

$19.00

−7% · range $19.00–19.00

Next earnings

Nov 5

in 9 days · EPS est. −$0.65

1 year

−12.4%

from $23.31 · Oct 27

30 days

−8.7%

from $22.36

52-week range

$13.79–30.85

−34% from high · low Mar 3

Avg volume 20D

270.3K

shares / day

Short interest

🔒 Subscribers only

Insider net

−$223.5K

0 buyers · 2 sellers · since Feb 24

New fund stakes

Q2 2026 13F · 1 exit

Filing reports

analyzed by SecBot

SecBot read BULLISH 3 reports · latest

Balance 0 bearish · 1 bullish · 2 neutral oldest → newest, height = score

Avg score

·High conf. 3/3 ·Next Earnings date, Nov 5, 2026

Strongest BULLISH Fulgent Genetics announced interim Phase 2 data for FID-007 + cetuximab in R/M HNSCC, showing a 60%…

All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

R May 21 Fulgent Genetics announced interim Phase 2 data for FID-007 + cetuxi…
S May 27 to Jun 2 2 days of insider sells: $106.3K by 2 insiders, avg $17.78
S Aug 27 to Sep 2 2 days of insider sells: $117.1K by 2 insiders, avg $19.75

Signal stack

Where each data set points today.

InsidersBEARISH

2 insiders sold $223.5K.
InstitutionsMIXED

Q2 2026: 21 added (0 new), 18 trimmed or exited.
AnalystsBEARISH

0 of 6 rate it Buy or better. Price is above every target.
TrendDOWNTREND

1% below its 50-day average.

Who's buying

13F· Q2 2026

new positions

exit

Fund	Move	Shares	Value
JACOBS LEVY EQUITY MANAGEMENT, INC	DOUBLED	782,116	$16.0M
JPMORGAN CHASE & CO	ADD	756,558	$15.5M
D. E. Shaw & Co., Inc.	TRIM	292,006	$6.0M
HRT FINANCIAL LP	DOUBLED	229,444	$4.7M
BANK OF AMERICA CORP /DE/	ADD	175,581	$3.6M
UBS Group AG	TRIM	174,952	$3.6M
CITADEL ADVISORS LLC	DOUBLED	174,180	$3.6M
Connor, Clark & Lunn Investment Management Ltd.	TRIM	159,108	$3.3M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

6 analysts

Sell 0% rate it Buy or better

Strong Buy0Buy0Hold3Sell1Strong Sell2

12-month targets · 1 analysts

$20.42 $19.00 $19.00 $19.00

Price is above the highest target. Median implies −7%.Targets as of Oct 27, 2026.

Recent actions

Date	Firm	Action	Rating
Aug 4, 2026	Piper Sandler MAINTAIN	MAINTAIN	Neutral
May 5, 2026	Piper Sandler REITERATE	REITERATE	Neutral

Insider ledger

Form 4

bought · 0 insiders

$223.5K

sold · 2 insiders

Date	Insider	Type	Value
Sep 2, 2026	Xie Jian President and COO	SELL	$41.8K
Sep 2, 2026	Gao Hanlin Chief Scientific Officer	SELL	$32.9K
Sep 1, 2026	Hsieh Ming Chief Executive Officer	TAX W/H	$86.0K
Sep 1, 2026	Kim Paul CFO and Treasurer	TAX W/H	$40.9K
Aug 27, 2026	Gao Hanlin Chief Scientific Officer	SELL	$18.7K
Aug 27, 2026	Xie Jian President and COO	SELL	$23.7K
Aug 26, 2026	Hsieh Ming Chief Executive Officer	TAX W/H	$58.4K
Aug 26, 2026	Kim Paul CFO and Treasurer	TAX W/H	$23.1K

Earnings setup

Estimates

Nov 5

reports in 9 days

−$0.65

EPS estimate, this quarter

Current-quarter EPS estimate

$0.000

90d

−$0.360

60d

−$0.360

30d

−$0.360

−$0.650

Now

Period	EPS est.	Range	30D rev.	Revenue
Current Q	-$0.65	-$0.65–-$0.65	-80.6%	$86.3M
Next Q	-$0.69	-$0.69–-$0.69	-86.5%	$88.9M
Current FY	-$2.27	-$2.27–-$2.27	-46.5%	$331.7M
Next FY	-$1.38	-$1.38–-$1.38	-20.0%	$382.7M